In conclusion, our study reveals a mechanism by which breast tumor evades the CD8+ T cell immune response and provides the rationale for potential therapy by targeting PGRN in combination with immune checkpoint inhibitors for breast cancer patients. This evidence concerns the gene GRN and breast carcinoma.